Related Experiment Video
Updated: May 9, 2026
10:49
Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
Published on: September 18, 2013
Targeted drug discovery for pediatric leukemia
Andrew D Napper1, Venita G Watson
1High-Throughput Screening and Drug Discovery Laboratory, Nemours Center for Childhood Cancer Research, A.I. duPont Hospital for Children , Wilmington, DE , USA.
Frontiers in Oncology
|July 13, 2013
Summary
New targeted therapies and drug combinations offer improved outcomes for high-risk pediatric leukemia. Understanding genetic signatures and target interconnections is key to developing effective, less toxic treatments for childhood leukemia.
Area of Science:
- Pediatric Oncology
- Cancer Genetics
- Pharmacology
Background:
- Pediatric leukemia treatment has advanced, yet poor response persists in some patients.
- High-risk childhood leukemia often presents with genetic alterations, including chromosomal rearrangements.
- Understanding leukemia's genetic and epigenetic landscape enables targeted therapy development.
Purpose of the Study:
- To review promising new drugs and drug combinations for high-risk pediatric leukemia.
- To present biological evidence supporting molecular target selection.
- To critically survey progress in novel molecular therapeutics for pediatric leukemia.
Main Methods:
- Literature review of recent advancements in pediatric leukemia therapeutics.
- Analysis of biological evidence for molecular target identification.
- Survey of pre-clinical and clinical studies of novel molecular therapeutics.
Main Results:
- Genetic signatures identify subsets of pediatric leukemia with poor prognosis.
- Targeted therapies show potential for greater efficacy and reduced toxicity.
- Synergistic effects observed between targeted therapies and conventional chemotherapy.
Conclusions:
- Novel targeted drugs and drug combinations are crucial for improving outcomes in high-risk pediatric leukemia.
- Understanding cancer's ability to circumvent single-target blockade is essential.
- Continued research into molecular therapeutics promises less toxic and more effective treatments.
Related Concept Videos
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:50Combination Therapies and Personalized Medicine
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
01:26Pharmacokinetics in Pediatric Patients: Drug Excretion
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
01:24Pharmacokinetics in Pediatric Patients: Drug Metabolism
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
01:26Drug Discovery: Overview
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...